Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Positive Data From Pfizer Alzheimer Biomarker Study

By Akili Interactive Labs, Inc. | December 14, 2016

Akili and Pfizer present positive data from digital biomarker study to detect subtle cognitive changes in healthy subjects at risk of developing Alzheimer’s disease.

Akili Interactive Labs, Inc. and Pfizer Inc. today presented positive topline data showing that Akili’s proprietary technology platform detected a statistically significant difference between subjects with and without brain amyloidosis, the primary biomarker for Alzheimer’s risk. The study was part of a collaborative trial designed by Pfizer and Akili, and topline results were presented at the International Conference on Clinical Trials for Alzheimer’s Disease in San Diego, CA.

The technology, derived from the company’s patent-pending cognitive measurement platform, differentiated between older healthy subjects positive for amyloid deposits in their brains versus an age-matched comparison group of amyloid-negative subjects, both in change over time (p=0.04) and at the completion visit after 28-day remote self-administration protocol (p<0.008). All metrics were obtained from study participant interaction with the cognitive assessment tool, which is designed to operate as a fast-paced action video game on a tablet. Importantly, compliance with the tool was high, and no safety concerns were reported during the study.

“These initial results suggest that our digital biomarkers may have the potential to serve as non-invasive options to screening procedures such as PET imaging scans requiring the administration of radioactive ligands or lumbar punctures,” said Eddie Martucci, president and CEO of Akili. “We’re also excited by the potential for early detection of neurological dysfunction, and we’re looking forward to further exploring that potential on our own and with strategic partners.”

“We are encouraged by the results of this trial, and we look forward to exploring ways that we might be able to implement innovative new technologies like the Akili platform into the clinical trial process,” said Ole Isacson, senior vice president and chief scientific officer, neuroscience, Pfizer. “Alzheimer’s disease is a particularly complex disease about which we still have much to learn. These results are a step in the right direction in our mission of making a difference in the lives of Alzheimer’s patients and their families.”

The non-exclusive collaboration between Akili and Pfizer was established in 2014 to assess the potential correlation between Akili’s proprietary digital biomarkers and one or more of the accepted neurological markers for asymptomatic Alzheimer’s Disease.

The double-blind study was conducted as a parallel protocol where individuals were accepted into the study only if they were judged healthy by screening criteria. All accepted individuals were then given a quantitative PET scan to determine brain amyloid presence, as amyloid accumulation is generally considered to be a biomarker and risk factor for eventual development of Alzheimer’s disease. All participants also received a full neurological work-up including magnetic resonance imaging (MRI) and non-Akili cognitive endpoints including measures of memory and attention. Further analyses of a variety of digital metrics from this study that correlate with the PET, MRI and other patient data are underway.

(Source: Business Wire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE